K Kajinami

Summary

Affiliation: Kanazawa Medical University
Country: Japan

Publications

  1. ncbi request reprint Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 175:287-93. 2004
  2. ncbi request reprint [Genetic testing and gene-based testing for hyperlipidemia and lipid metabolism disorders]
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University
    Nihon Rinsho 63:301-7. 2005
  3. ncbi request reprint Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi 920 0293, Japan
    Cardiovasc Drug Rev 21:199-215. 2003
  4. ncbi request reprint Cholesterol absorption inhibitors in development as potential therapeutics
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi, Kahoku gun 920 0293, Japan
    Expert Opin Investig Drugs 11:831-5. 2002
  5. ncbi request reprint Statin pharmacogenomics: what have we learned, and what remains unanswered?
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Uchinada, Japan
    Curr Opin Lipidol 16:606-13. 2005
  6. ncbi request reprint Statin response and pharmacokinetics variants
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
    Expert Opin Pharmacother 6:1291-7. 2005
  7. ncbi request reprint A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, USA
    Atherosclerosis 180:407-15. 2005
  8. ncbi request reprint Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku, Uchinada machi, Japan
    Am J Cardiol 92:1113-6. 2003
  9. ncbi request reprint Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 178:331-8. 2005
  10. ncbi request reprint ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    J Lipid Res 45:653-6. 2004

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 175:287-93. 2004
    ..The other ABCG5/G8 polymorphisms did not show any significant interactions with the CYP7A1 polymorphism. We conclude that the ABCG8 H19 and CYP7A1 C-204 alleles appear to interact in a dose-dependent manner on atorvastatin response...
  2. ncbi request reprint [Genetic testing and gene-based testing for hyperlipidemia and lipid metabolism disorders]
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University
    Nihon Rinsho 63:301-7. 2005
  3. ncbi request reprint Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi 920 0293, Japan
    Cardiovasc Drug Rev 21:199-215. 2003
    ..The efficacy and safety of higher dose treatment, as well as its long-term effects in the prevention of coronary artery disease, should be further investigated...
  4. ncbi request reprint Cholesterol absorption inhibitors in development as potential therapeutics
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi, Kahoku gun 920 0293, Japan
    Expert Opin Investig Drugs 11:831-5. 2002
    ..This approach in the treatment of lowering cholesterol appears to play a more significant role in the clinical field of atherosclerotic vascular disease...
  5. ncbi request reprint Statin pharmacogenomics: what have we learned, and what remains unanswered?
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Uchinada, Japan
    Curr Opin Lipidol 16:606-13. 2005
    ..The purpose of this review is to summarize recent progress in the research for exploring genetic determinants of clinical efficacy and safety of statin therapy...
  6. ncbi request reprint Statin response and pharmacokinetics variants
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
    Expert Opin Pharmacother 6:1291-7. 2005
    ..Future studies using these approaches could provide more striking evidence, which may be sufficient to justify genetic analysis regarding pharmacokinetic variants in the clinical practice of statin therapy...
  7. ncbi request reprint A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, USA
    Atherosclerosis 180:407-15. 2005
    ..We concluded that the CYP7A1 A-204C promoter variant was associated with poor response to atorvastatin, which were additively enhanced by common variants in another locus, APOE...
  8. ncbi request reprint Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku, Uchinada machi, Japan
    Am J Cardiol 92:1113-6. 2003
    ..The serial changes in 3 markers were favorable-increased bone formation markers and unchanged bone resorption marker-but the changes occurred only in patients with pretreatment vitamin D levels >50 pg/ml...
  9. ncbi request reprint Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 178:331-8. 2005
    ....
  10. ncbi request reprint ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    J Lipid Res 45:653-6. 2004
    ..These results suggest that, in patients with hypercholesterolemia, the ABCG8 D19H variant is associated with greater LDLC-lowering response to atorvastatin therapy...
  11. ncbi request reprint Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:1046-50. 2004
    ..Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism...
  12. ncbi request reprint Imbalance of sex hormone levels in men with coronary artery disease
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Uchinada, Japan
    Coron Artery Dis 15:199-203. 2004
    ..The aim of the study was to investigate the potential role of sex hormones in coronary atherosclerosis...
  13. ncbi request reprint Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
    Atherosclerosis 177:219-34. 2004
    ....
  14. ncbi request reprint NK-104: a novel synthetic HMG-CoA reductase inhibitor
    K Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi, Kahoku gun 920 0293, Japan
    Expert Opin Investig Drugs 9:2653-61. 2000
    ..NK-104 can provide a new and potentially superior therapeutic agent when compared with currently available other statins. Randomised controlled clinical trials to assess the long-term effects of this new statin on CAD would be required...
  15. ncbi request reprint Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases
    K Kajinami
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Mod Pathol 12:1174-80. 1999
    ..These observations suggest that the MMP-TIMP system appears to play a significant role in the development of coronary ectasia..
  16. ncbi request reprint Pharmacogenomics of statin responsiveness
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, Daigaku Uchinada, Japan
    Am J Cardiol 96:65K-70K; discussion 34K-35K. 2005
    ..In the future, pharmacogenomic studies with a greater number of participants (>2,000 participants) should provide a better picture as to who is most likely and who is least likely to benefit from statin therapy...
  17. ncbi request reprint Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group
    H Mabuchi
    Second Department of Internal Medicine, Kanazawa University School of Medicine, Japan
    Am J Cardiol 82:1489-95. 1998
    ..0088). It is concluded that LDL-apheresis is effective as treatment of CHD in FH heterozygotes, and may become the therapy of choice in severe types of FH...
  18. ncbi request reprint Catalytically inactive lecithin: cholesterol acyltransferase (LCAT) caused by a Gly 30 to Ser mutation in a family with LCAT deficiency
    X P Yang
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Ishikawa, Japan
    J Lipid Res 38:585-91. 1997
    ..Thus, the N-terminal domain appears crucial for enzymatic activity, in addition to the catalytically active consensus sequence of Gly179 to Gly183 and a putative sterol binding domain of Glu154 to Lys173...
  19. ncbi request reprint Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma
    A Inazu
    The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Takara machi, Japan
    Atherosclerosis 145:405-13. 1999
    ..In addition, higher levels of serum HDL3 triglyceride on lipid-lowering therapy (6 months) appear to be a common predictor of regression of Achilles' tendon xanthoma in the treatment with either pravastatin or probucol...
  20. ncbi request reprint Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis
    Y Noji
    The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Clin Chem Lab Med 39:380-4. 2001
    ....
  21. ncbi request reprint Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene
    X P Yang
    Second Department of Internal Medicine, Department of General Medicine School of Medicine, Kanazawa University, Takara machi 13 1 Kanazawa, Ishikawa 920 8641, Japan
    Arterioscler Thromb Vasc Biol 19:1950-5. 1999
    ..999). Maternal isodisomy (maternal UPD 4q) was the basis for homozygosity of the MTP gene mutation in this patient...
  22. ncbi request reprint Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group
    K Kajinami
    The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Am J Cardiol 85:178-83. 2000
    ....
  23. ncbi request reprint CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:104-7. 2004
    ....
  24. ncbi request reprint Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia
    A Inazu
    Second Department of Internal Medicine, School of Medicine, University of Kanazawa, Japan
    Horm Metab Res 24:284-8. 1992
    ..334, p less than 0.05). These results indicate that the enhanced CETP activities may contribute to increase risk for developing atherosclerosis in FH by changing the distribution of cholesteryl ester in serum lipoproteins...
  25. ncbi request reprint Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia
    M Kawashiri
    The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
    Am J Cardiol 86:840-5. 2000
    ..Thus, the MTHFR mutation appears to accelerate the onset of CAD through elevation of plasma homocysteine levels in male heterozygous patients with FH...
  26. ncbi request reprint Coronary calcification and coronary atherosclerosis: site by site comparative morphologic study of electron beam computed tomography and coronary angiography
    K Kajinami
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    J Am Coll Cardiol 29:1549-56. 1997
    ..We compared, on a site by site basis, the morphologic features of coronary calcifications determined by electron beam computed tomography (EBCT) and angiographically defined coronary atherosclerosis...
  27. ncbi request reprint Role of a novel conduction pattern around the coronary sinus in cavotricuspid isthmus dependent right atrial flutter
    Yoshio Yamaguchi
    Department of Cardiology, Kanazawa Medical University School of Medicine, Ishikawa
    J Cardiol 50:1-10. 2007
    ....
  28. ncbi request reprint Serum apolipoproteins in heterozygous familial hypercholesterolemia
    K Kajinami
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Clin Chim Acta 211:93-9. 1992
    ..34 +/- 0.07) was significantly lower than that in normal subjects (0.39 +/- 0.05). This difference might possibly be produced by an abnormal HDL metabolism of FH patients, a topic which remains to be elucidated by further investigation...
  29. ncbi request reprint Therapeutic effects of LDL apheresis in the prevention of atherosclerosis
    K Kajinami
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Curr Opin Lipidol 10:401-6. 1999
    ..Since the mechanisms of clinical improvement caused by LDL apheresis extend beyond simple and drastic reduction of LDL cholesterol, further investigation based on recent vascular biological evidence is needed...
  30. ncbi request reprint New variant of low density lipoprotein receptor gene. FH-Tonami
    K Kajinami
    Second Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa, Japan
    Arteriosclerosis 8:187-92. 1988
    ..Neonatal diagnosis of FH in two fetuses from one family was possible through analyses of their LDLR genes in cord blood samples at delivery...
  31. ncbi request reprint Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency
    Bela F Asztalos
    Lipid Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
    J Lipid Res 45:448-55. 2004
    ....
  32. ncbi request reprint Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia
    Yoshihiro Noji
    Molecular Genetics of Cardiovascular Disorders The Second Department of Internal Medicine, Vascular Medicine, Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
    Atherosclerosis 163:157-64. 2002
    ..As for the safety of pitavastatin, adverse reactions were observed in one case (4%) of subjective and objective symptoms. The effects of pitavastatin on TC and LDL-C were stable during long treatment of patients with heterozygous FH...
  33. ncbi request reprint Effects of serum B vitamins on elevated plasma homocysteine levels associated with the mutation of methylenetetrahydrofolate reductase gene in Japanese
    Yuri Moriyama
    Public Health Institute of Kochi Prefecture, Marunouchi 2 4 1, 780 0850, Kochi, Japan
    Atherosclerosis 164:321-8. 2002
    ..These findings suggest that elevated homocysteine levels among Japanese with the homozygous genotype for the MTHFR gene mutation can be modified efficiently by dietary supplement of vitamin B12 as well as folate...
  34. ncbi request reprint Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation test
    Norihiro Morikawa
    Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan
    Eur Heart J 28:2992-7. 2007
    ....